Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-MIND: Tafasitamab vs Rituximab in R/R DLBCL
NCT02763319Phase 3Completed
- Sponsor
- Incyte
- Start
- Nov 2016
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Incyte. Primary endpoints: Progression-Free Survival up to 41.4 months and Progression-Free Survival in NK Cell Count-Low Subgroup up to 46.5 months. Started Nov 2016; status: completed.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02763319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763319.